Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Transforming the Treatment Paradigm for Patients With MDS: Webcast
  • CME

Credits Available
Physicians: maximum of 2.0 AMA PRA Category 1 Credits
Released: December 9, 2020 Expiration: December 8, 2021
Start Activity
Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Bristol-Myers Squibb
Taiho Oncology Inc.
Guillermo Garcia-Manero, MD
Rami S. Komrokji, MD
Jamile Shammo, MD, FASCP, FACP

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Integrate novel management options for managing MDS-related anemia
  • Evaluate emerging treatment options for the treatment of patients with lower-, intermediate-, and high-risk MDS
  • Consider available treatment options and clinical trial enrollment for the management MDS
  • Plan novel therapeutic options for patients with relapsed/refractory disease
  • Identify patients with MDS who are candidates for ongoing clinical trials

Information on this Educational Activity

Faculty

Rami S. Komrokji, MD

Senior Member, Vice Chair
Malignant Hematology
Section Head
Leukemia and MDS
H. Lee Moffitt Cancer Center & Research Institute
Professor
Department of Oncologic Sciences
University of South Florida
Tampa, Florida

Rami Komrokji, MD, has disclosed that he has received consulting fees from AbbVie, Acceleron, Bristol-Myers Squibb, Geron, Incyte, and Jazz and non-CME/CE funding (speakers bureaus) from Agios, Bristol-Myers Squibb, and Jazz.
Guillermo Garcia-Manero, MD

Professor, Division of Cancer Medicine
Chief, Section of Myelodysplastic Syndromes
Division of Cancer Medicine
Department of Leukemia
The University of Texas MD Anderson Cancer Center
Houston, Texas

Guillermo Garcia-Manero, MD, has disclosed that he has received funds for research support from Bristol-Myers Squibb and consulting fees from Bristol-Myers Squibb and Taiho.
Jamile Shammo, MD, FASCP, FACP

Professor of Medicine and Pathology
Division of Hematology, Oncology, and Stem Cell Transplant
Director, MDS/MPN/Aplastic Anemia Program 
Rush University Medical Center
Chicago, Illinois

Jamile Shammo, MD, FASCP, FACP, has disclosed that she has received funds for research support from AbbVie, Alexion, Bristol-Myers Squibb, CTI, Incyte, Kartos, Novartis, Onconova, and Telios; consulting fees from Alexion, Appelis, Bristol-Myers Squibb, Incyte, and Novartis; fees for non-CME/CE services from Alexion, Bristol-Myers Squibb, Incyte, and Sanofi; and stock/ownership interest from AbbVie, Baxter, and Takeda.

Staff

Terrence Fagan

Associate Scientific Director

Terrence Fagan has no relevant conflicts of interest to report.
Marie N. Becker, PhD

Scientific Director

Marie N. Becker, PhD, has no relevant conflicts of interest to report.
Petra Cravens, PhD

Editorial Contributor

Petra Cravens, PhD, has no relevant conflicts of interest to report.
Timothy A. Quill, PhD

Associate Director, Scientific Services

Timothy A. Quill, PhD, has no relevant conflicts of interest to report.
Kevin Obholz, PhD

Senior Director, Educational Strategy

Kevin Obholz, PhD, has no relevant conflicts of interest to report.
Jason Everly, PharmD

Director, Program Development and Educational Impact

Jason Everly, PharmD, BCOP, CHCP, has no relevant conflicts of interest to report.
June Wasserstrom

Director, CME Program Development

June Wasserstrom has no relevant conflicts of interest to report.

Target Audience

This program is intended for hematologists-oncologists and other clinicians involved in the management of patients with MDS.

Goal

The goal of this activity is to improve the knowledge, competence, and performance of learners to apply the latest practice-changing data in the individualized clinical management of patients with MDS.

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 2.0 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from December 09, 2020, through December 08, 2021:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Transforming the Treatment Paradigm for Patients With MDS: Webcast
  • CME

Loading...
Watch this on-demand Webcast capturing a live CCO Webinar to learn the latest evidence for optimizing treatment of patients with myelodysplastic syndromes (MDS).
Guillermo Garcia-Manero, MD
Rami S. Komrokji, MD
Jamile Shammo, MD, FASCP, FACP
Physicians: maximum of 2.0 AMA PRA Category 1 Credits
Released: December 9, 2020 Expiration: December 8, 2021

Related Content

person default Ashley Leak Bryant, PhD, RN, OCN, FAAN Sara Tinsley, PhD, APRN, AOCN Released: November 29, 2021

Downloadable short slideset from CCO on recognizing and managing ocular toxicities associated with antibody–drug conjugates.

Asim V. Farooq, MD Joann Kang, MD Paul G. Richardson, MD Released: November 29, 2021

Amer M. Zeidan, MBBS, discusses novel and investigational therapies for treating patients with myelodysplastic syndromes (MDS) in this commentary from Clinical Care Options (CCO)

Amer Zeidan, MBBS Released: November 22, 2021

Downloadable PDF with expert answers to clinicians’ questions on the care of patients with lymphomas during COVID-19, from Clinical Care Options (CCO)

John Allan, MD Sandra E. Kurtin, PhD, ANP-C, AOCN Released: November 18, 2021
Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Bristol-Myers Squibb
Taiho Oncology Inc.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue